Latest News of PHR
Humphrey Bogart, Lauren Bacall's son says young people 'not aware of the past,' don't know his famous parents
By Fox News |
2 days ago
William J. Mann's book "Bogie & Bacall: The Surprising True Story of Hollywood's Greatest Love Affair" explores the iconic Hollywood couple. Stephen Bogart, son of Humphrey Bogart and Lauren Bacall, a...
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
By Forbes |
6 days ago
Stocks of major drug makers and biotech companies plummeted as Donald Trump expressed interest in appointing vaccine skeptic Robert F. Kennedy Jr. as head of the U.S. Department of Health and Human Se...
AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials
By Yahoo! Finance |
1 week ago
AbbVie's stock plummeted by 12% after its anti-psychotic drug, emraclidine, failed to meet primary endpoints in Phase II trials for schizophrenia treatment....
-
PhRMA shells out to get PBM reform over finish line
By POLITICO | 1 week agoPhRMA launches a seven-figure ad blitz to push for a crackdown on pharmaceutical middlemen, focusing on saving benefits for patients. The push is part of a final sprint to pass PBM reforms in the lame...
-
Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints
By MarketWatch | 1 week agoBristol Myers Squibb's stock rose by 12.5% following AbbVie's announcement of disappointing trial results for their new schizophrenia drug, causing AbbVie's shares to drop by 12.4%....
-
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
By MarketWatch | 1 week agoAbbVie's stock dropped significantly as their schizophrenia drug, emraclidine, failed to show significant improvement in two Phase 2 trials. The drug did not meet the primary endpoint of demonstrating...
-
AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
By Yahoo! Finance | 1 week agoAbbVie Inc. faces a setback as its drug for schizophrenia failed in trials, causing shares to drop significantly. This news benefits Bristol Myers Squibb Co., which recently gained approval for a new ...
-
Investing in Sphere Entertainment (NYSE:SPHR) three years ago would have delivered you a 14% gain
By Yahoo! Finance | 2 weeks agoInvestors aiming to outperform market index funds need to carefully select stocks. Sphere Entertainment Co. (NYSE:SPHR) has seen a 47% drop in share price over 3 years, with revenue declining annually...
-
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
By Forbes | 2 weeks agoThe newly approved schizophrenia drug, Cobenfy, offers a novel treatment approach targeting cholinergic receptors. Despite its potential benefits, challenges like high cost and insurance coverage rest...
-
From 'When Harry Met Sally' to 'Sleepless in Seattle': Nora Ephron's legacy
By Newsweek | 2 weeks agoJournalist Ilana Kaplan reminisces about Nora Ephron's impact on romantic comedies, highlighting the director's influence on complex female characters, empowering feminism, and the intertwining of per...
-
Teva's long-lasting schizophrenia injectable shines in Phase III
By Yahoo! Finance | 2 weeks agoTeva Pharmaceuticals' TEV-479 (olanzapine) showed significant improvements in schizophrenia symptoms and quality of life in a Phase III trial. The study revealed positive results across different dose...
-
A promising schizophrenia drug showed mixed results. What does that mean for patients?
By AP NEWS | 3 weeks agoA new schizophrenia drug, Cobenfy, shows promise with minimal side effects and weight loss benefits. However, high dropout rates in trials highlight challenges in treating schizophrenia. Patients' exp...
-
Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia
By Yahoo! Finance | 3 weeks agoZai Lab's Phase III trial of KarXT for schizophrenia in China showed positive outcomes, meeting primary and secondary endpoints. The trial demonstrated the potential of KarXT as a new treatment option...
-
Olivia Rodrigo Reveals Hilarious British Phrase She Repeated Before Every Guts Tour Show: 'Very Superstitious' (Exclusive)
By PEOPLE.com | 3 weeks agoRachel DeSantis, a senior writer at PEOPLE since 2019, covers music. Olivia Rodrigo shared her pre-show ritual and superstitions during her GUTS world tour, which ended after nearly 100 shows....
-
Revisiting PhRMA's drug-pricing pitch to Trump
By POLITICO | 3 weeks agoIn 2017, PhRMA presented a plan to Trump focusing on drug pricing. The group aimed to influence his policies by emphasizing value-based contracting and targeting pharmacy benefit managers. Challenges ...